A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

Respiratory syncytial virus (RSV), or human respiratory syncytial virus (hRSV), is a common viral respiratory infection that triggers mild, cold-like symptoms. However, at-risk populations ...

This flu season has been a difficult one. Not only are a lot of people getting sick, but more people are getting very sick ...

Three of the viruses — flu, COVID-19 and RSV — are respiratory viruses and spread from person to person through germ-filled ...

The number of flu-related deaths in North Carolina has climbed to 362, the N.C. Department of Health and Human Services ...

For the week starting on Feb 3, the positivity rate of flu climbed slightly by 1.2 percentage points from the previous week ...

Porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs is economically devastating for the global ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our ...